Key phase III trials have demonstrated superior efficacy and PFS with afatinib versus standard chemotherapy regimens in patients with NSCLC exhibiting Ex19del and L858R mutations in EGFR, with superior OS also observed in the Ex19del cohorts (52–54). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.